Frontage Labs to expand key facilities
- Frontage Labs is expanding a key facilities: the chemistry, manufacturing and control (CMC) facility in Exon, Pennsylvania.
- The goal is to increase capacity and allow for future growth that will enable Frontage to keep up with demand for full-service support of pharma R&D efforts.
- This is a two-phase renovation starting with enhancing existing facilities and then adding on additional CTM space.
Frontage Labs is experiencing significantly increased demands as pharma companies start to lean more on CROs to get critical work accomplished, including organic synthesis, formulation development, GMP analytical testing, and CTM. Frontage develops solid, semi-solid, liquid and sterile dosage forms that are used in clinical trials in the US, the EU and Asia.
The Frontage expansion will have two phases. Phase one involves enhancing existing facilities, including an additional 8,000 square feet of office space. During phase two, the company will add more CTM space, as well as additional space to handle packaging, labeling and distribution---all part of their service offerings in addition to core support from discovery through late-stage development. The demand is there, especially as pharma companies face patent expiry and high development costs.
- Pharmaceutical Business Review Frontage Labs plans to expand chemistry, manufacturing and controls facility